EN DE
Watch Orchestra BioMed Holdings Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Orchestra BioMed Holdings Inc. (OBIO) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Orchestra BioMed Holdings Inc. stock $4.14, price $7.12, that is 41.9% below the price, quality 41 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US68572M1062

OB Orchestra BioMed Holdings Inc. logo Thin data Nov 14, 2026

Orchestra BioMed Holdings Inc.

OBIO · US

Far too expensive (fair value 42% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Quality 41/100 
Mixed Growth (revenue 5y +42.5 %/yr in USD) 
Insiders bought $310,204 (6M) · sold $439,050 
Revenue last quarter 89% below a year ago. 
Fair value $4.14 · Strongly overvalued 
Loss-making · -182.5% net margin (TTM) 
Negative free cash flow 
Trails peers (1/10) 
Narrow moat 8/100 · thin data
Thin data 
Estimate
Watch Orchestra BioMed Holdings Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$22.18 $2.35 Fair Value $4.14 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range $2.35 – $22.18 · fair‑value band $3.11 – $5.18 · the $7.12 price screens above the $4.14 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Orchestra BioMed Holdings in your weekly email

Every Wednesday you see whether Orchestra BioMed Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.

Show moreShow less

The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.

It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.

In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures.

It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease.

Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.

Stock analysis

Orchestra BioMed Holdings Inc. (OBIO) currently trades at $7.12, while our estimate is $4.14, 42% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $3.11 (bear) to $5.18 (bull), the price of $7.12 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Orchestra BioMed Holdings Inc. reported revenue of $33.5M in FY2025 versus −$782K in FY2021. Reported net income was −$52.7M in FY2025.

Key figures

Market cap $454M Small · P/S ratio 15.5 · EPS (TTM) $−0.7600 · Return on equity −182% · Return on assets (EBIT) −75.8% (5-year average) · Operating margin −195% · Revenue (TTM) $31.2M · Revenue growth (YoY) −89.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 2% below its 52-week high and 104% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −42%, OBIO screens richer than that median.

Fair Value

Bear $3.11 Fair Value $4.14 Bull $5.18
Price $7.12 · Downside -41.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 13
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 68
Debt, balance sheet and risk of trouble
Investment 79
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 87
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 98
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 6 officers or directors bought shares worth $310,204, most recently on Nov 9, 2026. Over the same period, one person sold shares worth $439,050. Buying cluster

  • BuyRTW INVESTMENTS, LP10% owner1,200,000 shares at $5.00$6.0MNov 9, 2026
  • BuyAndrew Lawrence TaylorChief Financial Officer1,000 shares at $5.00$5,000Nov 9, 2026
  • BuyDavid P HochmanOfficer, Director5× since Mar 13, 2026: 35,000 shares, avg. $4.39$153,800Nov 9, 2026
  • BuyDavid PacittiDirector20,000 shares at $5.00$100,000Nov 9, 2026
  • BuyEric S FainDirector2× since May 14, 2026: 40,000 shares, avg. $4.57$182,600Nov 9, 2026
  • SaleDarren ShermanOfficer, Director6× since Jun 1, 2026: 90,000 shares, avg. $4.88$439,050Nov 2, 202610b5-1 plan
  • BuyDarren ShermanOfficer, Director2,000 shares at $5.33$10,660Aug 26, 2026
  • BuyJason AryehDirector2× since May 15, 2026: 9,636 shares, avg. $3.89$37,481May 18, 2026
  • SaleRTW INVESTMENTS, LP10% owner32 shares at $4.13$132Apr 27, 2026

Plus 17 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+1,169.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+111.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.5%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−328.8% (2020) → −154.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

OBIO screens overvalued: fair value 42% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Orchestra BioMed Holdings Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Above median
Fair Value upside −41.9% · Bottom 25%
Profitability
Return on assets −45.9% · Below median
Net margin (12 months) −182.5% · Bottom 25%
Operating margin (12 months) −195.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −89.4% · Bottom 25%
Balance sheet
Debt / equity 0.23× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 7.17× · Priciest 25%
P/S (12 months) 14.56× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)0 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)89 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs OBIO
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs OBIO
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs OBIO
argenx SE ARGX $950.95 $908.40 −4% vs OBIO
CSL Limited CSL A$199.55 A$186.49 −7% vs OBIO
Moderna, Inc MRNA $215.27 $135.64 −37% vs OBIO
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs OBIO
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs OBIO
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs OBIO
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs OBIO

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Orchestra BioMed Holdings Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Orchestra BioMed Holdings Inc. Fair Value". https://www.fairvalue-calculator.com/stock/OBIO

Frequently asked questions

Is Orchestra BioMed Holdings Inc. (OBIO) overvalued or undervalued?
As of Nov 14, 2026, our estimate of fair value is $4.14 versus a price of $7.12, about 42% lower (overvalued).
What is the fair value of OBIO?
Our estimate for Orchestra BioMed Holdings Inc. is $4.14 (as of Nov 14, 2026), built from audited fundamentals. The current price: $7.12.
What is the quality score of OBIO?
Orchestra BioMed Holdings Inc. has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Orchestra BioMed Holdings Inc. (OBIO)?
Our calculated price target is the estimate of $4.14 (as of Nov 14, 2026). Cautious scenario $3.11, optimistic scenario $5.18. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Orchestra BioMed Holdings Inc. stock forecast for 2026?
Our estimate puts fair value at $4.14, about 42% lower versus a price of $7.12 (overvalued). Cautious scenario $3.11, optimistic scenario $5.18. The calculation is refreshed regularly with new filings.
What is the revenue of Orchestra BioMed Holdings Inc. (OBIO)?
Orchestra BioMed Holdings Inc. reported trailing-twelve-month revenue of about $31.2M (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Orchestra BioMed Holdings Inc. (OBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Orchestra BioMed Holdings Inc. it is $4.14 per share (as of Nov 14, 2026), against a price of $7.12.
Is Orchestra BioMed Holdings Inc. stock overvalued or undervalued in 2026?
As of Nov 14, 2026, OBIO trades above its calculated fair value: price $7.12, fair value $4.14, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OBIO?
No. The price is what the market pays today ($7.12); the fair value is what the company's own numbers justify ($4.14). For Orchestra BioMed Holdings Inc. the two are $2.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Orchestra BioMed Holdings Inc. worth?
The market values Orchestra BioMed Holdings Inc. at about $454M (market capitalisation, as of Nov 14, 2026). Per share that is $7.12; our models calculate a fair value of $4.14 per share.
What do the bullish and bearish scenarios say about OBIO?
Our models span a range for Orchestra BioMed Holdings Inc.: cautious scenario $3.11, base $4.14, optimistic $5.18 per share (as of Nov 14, 2026, price $7.12). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Orchestra BioMed Holdings Inc. (OBIO)?
Balance-sheet figures for Orchestra BioMed Holdings Inc. (as of Nov 14, 2026): return on equity −182.3%, debt of 0.23 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is OBIO from its 52-week high?
Orchestra BioMed Holdings Inc. trades at $7.12, about 2% below its 52-week high of $7.25 and 104% above the low of $3.49 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $4.14 is for.
Which stocks are comparable to Orchestra BioMed Holdings Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Orchestra BioMed Holdings Inc. stock attractive at the current price?
The data as of Nov 14, 2026: price $7.12, calculated fair value $4.14 (−42%), Quality Score 41/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Orchestra BioMed Holdings Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Orchestra BioMed Holdings Inc. (OBIO)?
The closing price on Nov 16, 2026 was $7.12. Our estimate is $4.14, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Orchestra BioMed Holdings Inc. right now?
The price sits above even our optimistic bull case ($5.18). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Orchestra BioMed Holdings Inc.

How large is the market capitalisation of Orchestra BioMed Holdings Inc. (OBIO)?
The market capitalisation of Orchestra BioMed Holdings Inc. is $454M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Orchestra BioMed Holdings Inc. (OBIO)?
The price-to-sales ratio of Orchestra BioMed Holdings Inc. is 15.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Orchestra BioMed Holdings Inc. (OBIO)?
Earnings per share at Orchestra BioMed Holdings Inc. are $−0.7600. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Orchestra BioMed Holdings Inc. (OBIO)?
The return on equity (ROE) of Orchestra BioMed Holdings Inc. is −182% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Orchestra BioMed Holdings Inc. (OBIO)?
On an EBIT basis the return on assets of Orchestra BioMed Holdings Inc. is −75.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Orchestra BioMed Holdings Inc. (OBIO)?
The operating margin of Orchestra BioMed Holdings Inc. is −195% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Orchestra BioMed Holdings Inc. (OBIO)?
Revenue at Orchestra BioMed Holdings Inc. is down 89.4% versus a year earlier (3y avg +112%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Orchestra BioMed Holdings Inc. (OBIO) generate?
The free cash flow of Orchestra BioMed Holdings Inc. is −$49.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Orchestra BioMed Holdings Inc. (OBIO) hold?
Orchestra BioMed Holdings Inc. holds more cash than debt, $33.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Orchestra BioMed Holdings Inc. in the live analysis

One click puts Orchestra BioMed Holdings Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.